E2F1 and neoplasm: As E2F1-HMGCR is critical for ferroptosis-resistance of immune-refractory tumor cells, we reasoned that pharmacological inhibition of HMGCR might be an effective strategy for targeting immune-refractory tumor cells that highly express E2F1.